Effect of interval hypoxic therapy in the hypoxia-hyperoxia mode on the hemostatic system of patients who have suffered a new coronavirus infection COVID-19

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. The positive effect of interval hypoxic therapy in the treatment of many diseases has become the basis for its use in rehabilitation after a new coronavirus infection to normalize disorders of the hemostatic system.

Aim. To identify the peculiarities of the interval hypoxic therapy effect on the hemostatic system of patients who have suffered a new coronavirus infection.

Material and methods. The work was carried out from April 2020 to May 2022. 220 men aged 45–59 years (average age 48.8±2.4 years) were examined. The main group included 90 people who had a moderate coronavirus infection a month ago; the control group (n=70) was represented by relatively healthy people; the comparison group (n=60) suffered coronavirus infection and underwent standard rehabilitation without hypoxic therapy. The content of platelets, D-dimer, international normalized ratio, prothrombin time, activated partial thromboplastin time, antithrombin III activity, interleukin-6 level, and C-reactive protein content in the blood serum was determined. To assess statistically significant differences, a parametric method applying paired and unpaired Student's t-test was used. Differences were considered statistically significant at p <0.05.

Results. In patients of the main group, a violation of the hemostatic system, indicating increased thrombogenicity of the blood against the background of persistent inflammatory activity, was revealed. After interval hypoxic therapy, the platelet count increased to 215.53±23.57×109/l (p=0.035), activated partial thromboplastin time to 26.74±1.84 s (p=0.035), international normalized ratio to 0.89±0.06 (p=0.005), antithrombin III activity in the blood up to 81.81±4.33% (p=0.007); the level of fibrinogen decreased to 3.86±1.09 g/l (p=0.035) and the content of D-dimer in the blood to 255.58±17.36 ng/ml (p=0.035). There was a decrease in the level of interleukin-6 to 6.03±0.65 pg/ml (p=0.035) and C-reactive blood protein to 1.03±0.15 mg/l (p=0.035).

Conclusion. Interval hypoxic therapy had a normalizing effect on the hemostatic system of patients who suffered a new coronavirus infection, as a result of suppressing the inflammatory process in the body.

Full Text

Restricted Access

About the authors

Indira A. Misirova

Kabardino-Balkarian State University named after Kh.M. Berbekov

Email: misirovaindira@mail.ru
ORCID iD: 0000-0002-9351-315X

Аssistant, Depart. of Normal and Pathological Physiology

Russian Federation, Nalchik, Russia

Omari-Butta A. Tsuntaev

Kabardino-Balkarian State University named after Kh.M. Berbekov

Email: Mikrobiologiaa@mail.ru
ORCID iD: 0009-0000-5748-1157

student

Russian Federation, Nalchik, Russia

Madina V. Merzhoeva

Kabardino-Balkarian State University named after Kh.M. Berbekov

Email: madina.merzhoeva.94@mail.ru
ORCID iD: 0009-0000-3176-9099

student

Russian Federation, Nalchik, Russia

Makka V. Merzhoeva

Kabardino-Balkarian State University named after Kh.M. Berbekov

Email: merzhoyeva.makka@mail.ru
ORCID iD: 0009-0007-2403-4714

student

Russian Federation, Nalchik, Russia

Irina Kh. Borukaeva

Kabardino-Balkarian State University named after Kh.M. Berbekov

Author for correspondence.
Email: irborukaeva@yandex.ru
ORCID iD: 0000-0003-1180-228X
SPIN-code: 9102-2336
Scopus Author ID: 23471777400

M.D., D. Sci. (Med.), Assoc. Prof., Head of Depart., Depart. of Normal and Pathological Phy­siology

Russian Federation, Nalchik, Russia

References

  1. Abdurakhimov AKh, Khegay LN, Yusupova ShK. COVID-19 and its complications. Re-health journal. 2021;(4):61–65. (In Russ.)
  2. Karelina SI, Kashpur YaO, Kosareva EA. Analysis of statistical data for the epidemic period from 2020 to 2023 of the new coronavirus infection on the territory of the Russian Federation and its subjects according to the data of the media. Universum: meditsina i farmakologiya. 2023;(4–5):42–46. (In Russ.)
  3. Yokota Sh, Kuroyva E, Nishioka K. Novel coronavirus disease (COVID-19) and “cytokine storms”. For more effective treatments from the viewpoints of an inflammatory pathophysiology perspective. Infectious diseases: News, Opinions, Training. 2020;9(4):13–25. (In Russ.) doi: 10.33029/2305-3496-2020-9-4-13-25.
  4. Khaytovich AB, Yermachkova PA. Pathogenesis of COVID-19. Tavricheskiy mediko-biologicheskiy vestnik. 2020;23(4):113–132. (In Russ.) doi: 10.37279/2070-8092-2020-23-4-113-132.
  5. Borukaeva IKh, Abazova ZKh, Ragimbekova MR, Temirzhanova FKh. Effect of interval hypoxytherapy and entеral oxygenotherapy on immunological reactivity in patients with bronchal asthma. Russian Journal of Immunology. 2019;13(2-1):174–176. (In Russ.) doi: 10.31857/S102872210006443-2.
  6. Abazova ZKh, Borukaeva IKh, Kumykov VK, Shibzukhova LA. Efficiency of hypoxic therapy at subclinical thyroid dysfunction with autoimmune genesis. Russian Journal of Immunology. 2019;22(2-1):124–126. (In Russ.) doi: 10.31857/S102872210006423-0.
  7. Ignatenko GA, Majlyan EA, Dubovaya AV, Kaluga AA, Goncharov AN, Subbotina EA. Substantiation of interval hypoxic therapy for autoimmune thyroiditis treatment in women. Prakticheskaya meditsina. 2023;21(2):31–37. (In Russ.) doi: 10.32000/2072-1757-2023-2-68-72.
  8. Cummins EP, Keogh CE, Crean D, Taylor CT. The role of HIF in immunity and inflammation. Mol Aspects Med. 2016;47(48):24–34. doi: 10.1016/j.mam.2015.12.004.
  9. Harris AJ, Thompson AR, Whyte MK, Walmsley SR. HIF-mediated innate immune responses: Cell signaling and therapeutic implications. Hypoxia (Auckl). 2014;2:47–58. doi: 10.2147/HP.S50269.
  10. Titova ON, Kuzubova NA, Lebedeva ES. The role of the hypoxia signaling pathway in cellular adaptation to hypoxia. RMJ. Medical review. 2020;4(4):207–213. (In Russ.) doi: 10.32364/2587-6821-2020-4-4-207-213.
  11. Moskalenko SV, Shakhmatov II, Kovalev IV, Shakhmatova KI, Vdovin VM. Reaction of the hemostatic system in response to hypercapnic hypoxia of maximum intensity depending on different types of preconditioning. Kazan Medical Journal. 2019;100(4):642–649. (In Russ.) doi: 10.17816/KMJ2019-642.
  12. Volovets SA, Tsyganova TN, Badalov NG. The effectiveness of hypo-hyperoxic training in the medical rehabilitation of patients who have undergone COVID-19. Russian journal of physiotherapy, balneology and rehabilitation. 2022;21(1):35–45 (In Russ.) doi: 10.17816/rjpbr109501.
  13. Normobaricheskaya gipoksiterapiya. Metodicheskiye rekomendatsii Ministerstva zdravookhraneniya Rossiyskoy Federatsii. (Normobaric hypoxic therapy. Methodological recommendations of the Ministry of Health of the Russian Federation.) M.: PAIMS; 2001. 16 р. (In Russ.)
  14. Tsyganova TN, Bobrovnitskiy IP. Apparat dlya gipo-, giperoksiterapii. (Apparatus for hypo-, hyperoxytherapy.) Patent for invention of the RF №2301686. Bull. No. 1 issued at 27.06.2007. (In Russ.)
  15. Becker RC. COVID-19 update: COVID-19-associated coagulopathy. J Thromb Thrombolysis. 2020;50(1):54–67. doi: 10.1007/s11239-020-02134-3.
  16. Lodigiani C, Iapichino G, Carenzo L, Cecconi M, Ferrazzi P, Sebastian T, Kucher N, Studt JD, Sacco C, Bertuzzi A, Sandri MT, Barco S; Humanitas COVID-19 Task Force. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020;191:9–14. doi: 10.1016/j.thromres.2020.04.024.

Supplementary files

Supplementary Files
Action
1. JATS XML

© 2023 Eco-Vector





This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies